Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Mexican Stock Exchange  >  Genomma Lab Internacional SAB de CV    LAB B   MX01LA010006

GENOMMA LAB INTERNACIONAL SAB DE CV (LAB B)
My previous session
Most popular
  Report  
End-of-day quote. End-of-day quote  - 01/18
13.2 MXN   +0.38%
2013GENOMMA LAB INTERNACIONAL SAB DE CV : quaterly earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mexican Stock Exchange
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
12.2(c) 12.2(c) 12.49(c) 13.15(c) 13.2 Last
4 109 242 3 057 573 8 705 464 4 212 706 2 754 732 Volume
-5.13% 0.00% +2.38% +5.28% +0.38% Change
More quotes
Financials (MXN)
Sales 2018 12 401 M
EBIT 2018 2 533 M
Net income 2018 1 293 M
Debt 2018 3 456 M
Yield 2018 -
Sales 2019 12 611 M
EBIT 2019 2 706 M
Net income 2019 1 332 M
Debt 2019 3 227 M
Yield 2019 3,67%
P/E ratio 2018 9,96
P/E ratio 2019 9,15
EV / Sales2018 1,39x
EV / Sales2019 1,35x
Capitalization 13 843 M
More Financials
Company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such... 
Sector
Pharmaceuticals
Calendar
02/21Earnings Release
More about the company
Surperformance© ratings of Genomma Lab Internacional
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMMA LAB INTERNACIONAL
2018GENOMMA LAB INTERNACIONAL DE CV : IFC and IDB Invest Will Provide a US$100 Milli..
AQ
2013GENOMMA LAB INTERNACIONAL SAB DE CV : Anuncio Wal-mart - TCP
PU
2013GENOMMA LAB INTERNACIONAL SAB DE CV : quaterly earnings release
2013Mexico's Genomma Lab to Sell Products in U.S. Wal-Mart Stores
DJ
2012GENOMMA LAB INTERNACIONAL SAB DE CV : GLI Secures Committed Financing to acquire..
PU
2011GENOMMA LAB : Termination of XL-3 License Agreement
PU
More news
Analyst Recommendations on GENOMMA LAB INTERNACIONAL
More recommendations
Sector news : Pharmaceuticals - NEC
01/18ELI LILLY AND : Lilly Reports Favorable Cyramza Results in Phase 3 Liver Cancer ..
DJ
01/18ABBVIE : Says Imbruvica Didn't Meet Endpoints in Pancreatic Cancer Study
DJ
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/18FDA Approves Herceptin Biosimilar Ontruzant Breast Cancer Drug
DJ
01/18ELI LILLY AND : Sarcoma Drug Combo Proves Ineffective in Trials--Update
DJ
More sector news : Pharmaceuticals - NEC
Chart GENOMMA LAB INTERNACIONAL SAB DE CV
Duration : Period :
Genomma Lab Internacional SAB de CV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOMMA LAB INTERNACIONAL
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 20,3  MXN
Spread / Average Target 54%
EPS Revisions
Managers
NameTitle
Jorge Luis Brake Valderrama Chief Executive Officer
Rodrigo Alonso Herrera Aspra Chairman
Antonio Zamora Galland Vice President-Administration & Finance
Juan Alonso Independent Director
Sabrina Lucila Herrera Aspra Director
Sector and Competitors
1st jan.Capitalization (M$)
GENOMMA LAB INTERNACIONAL SAB DE CV13.11%726
JOHNSON & JOHNSON0.03%350 508
PFIZER-2.70%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291